Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-intensity Induction with Venetoclax

Overview

Journal Am J Hematol

Specialty Hematology

Date 2020 Dec 1

PMID 33259075

Citations 4

Authors

Stacy Diao

E Dan Nichols

Courtney DiNardo

Marina Konopleva

Jing Ning

Wei Qiao

Abhishek Maiti

Adam J DiPippo

Affiliations

Soon will be listed here.

Citing Articles

Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S Eur J Haematol. 2024; 114(4):626-635.

PMID: 39726154 PMC: 11880964. DOI: 10.1111/ejh.14371.

BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond.

Wei A, Roberts A Hemasphere. 2023; 7(6):e912.

PMID: 37304937 PMC: 10256369. DOI: 10.1097/HS9.0000000000000912.

[Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].

Sun L, Ye S, Zhou N, Han X, Qi J, Liu X Zhonghua Xue Ye Xue Za Zhi. 2023; 43(10):826-832.

PMID: 36709196 PMC: 9669628. DOI: 10.3760/cma.j.issn.0253-2727.2022.10.005.

The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.

Pelosi E, Castelli G, Testa U Mediterr J Hematol Infect Dis. 2022; 14(1):e2022080.

PMID: 36425147 PMC: 9652018. DOI: 10.4084/MJHID.2022.080.

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia.

Maiti A, Konopleva M Cancer J. 2022; 28(1):2-13.

PMID: 35072368 PMC: 8785772. DOI: 10.1097/PPO.0000000000000567.

References

DiNardo C, Maiti A, Rausch C, Pemmaraju N, Naqvi K, Daver N . 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020; 7(10):e724-e736. PMC: 7549397. DOI: 10.1016/S2352-3026(20)30210-6. View

Seymour J, Ma S, Brander D, Choi M, Barrientos J, Davids M . Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017; 18(2):230-240. PMC: 5316338. DOI: 10.1016/S1470-2045(17)30012-8. View

Roeker L, Fox C, Eyre T, Brander D, Allan J, Schuster S . Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019; 25(14):4264-4270. PMC: 8020996. DOI: 10.1158/1078-0432.CCR-19-0361. View

Cairo M, Bishop M . Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004; 127(1):3-11. DOI: 10.1111/j.1365-2141.2004.05094.x. View

DiNardo C, Tiong I, Quaglieri A, MacRaild S, Loghavi S, Brown F . Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803. PMC: 7068032. DOI: 10.1182/blood.2019003988. View